These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19370366)

  • 1. Developing novel approaches to improve binding energy estimation and virtual screening: a PARP case study.
    Novikov FN; Stroylov VS; Stroganov OV; Kulkov V; Chilov GG
    J Mol Model; 2009 Nov; 15(11):1337-47. PubMed ID: 19370366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.
    Zeifman AA; Stroylov VS; Novikov FN; Stroganov OV; Zakharenko AL; Khodyreva SN; Lavrik OI; Chilov GG
    J Mol Model; 2012 Jun; 18(6):2553-66. PubMed ID: 22069029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the effect of PARP-1 flexibility in docking studies.
    Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
    J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
    Costantino G; Macchiarulo A; Camaioni E; Pellicciari R
    J Med Chem; 2001 Nov; 44(23):3786-94. PubMed ID: 11689065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking study and binding free energy calculation of poly (ADP-ribose) polymerase inhibitors.
    Ohno K; Mitsui T; Tanida Y; Matsuura A; Fujitani H; Niimi T; Orita M
    J Mol Model; 2011 Feb; 17(2):383-9. PubMed ID: 20480380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
    Cao R
    J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.
    Perkins E; Sun D; Nguyen A; Tulac S; Francesco M; Tavana H; Nguyen H; Tugendreich S; Barthmaier P; Couto J; Yeh E; Thode S; Jarnagin K; Jain A; Morgans D; Melese T
    Cancer Res; 2001 May; 61(10):4175-83. PubMed ID: 11358842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
    Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design.
    Khizer H; Maryam A; Ansari A; Ahmad MS; Khalid RR
    Arch Biochem Biophys; 2024 Jun; 756():110010. PubMed ID: 38642632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
    Lehtiö L; Jemth AS; Collins R; Loseva O; Johansson A; Markova N; Hammarström M; Flores A; Holmberg-Schiavone L; Weigelt J; Helleday T; Schüler H; Karlberg T
    J Med Chem; 2009 May; 52(9):3108-11. PubMed ID: 19354255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking.
    Zeng H; Zhang H; Jang F; Zhao L; Zhang J
    Chem Biol Drug Des; 2011 Sep; 78(3):333-52. PubMed ID: 21585709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing PARP1-inhibitor complexes for the development of novel inhibitors.
    Saqib U; Baig MS
    Cell Mol Biol (Noisy-le-grand); 2014 Oct; 60(3):43-52. PubMed ID: 25346248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
    J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead finder: an approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual screening.
    Stroganov OV; Novikov FN; Stroylov VS; Kulkov V; Chilov GG
    J Chem Inf Model; 2008 Dec; 48(12):2371-85. PubMed ID: 19007114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase.
    Menear KA; Adcock C; Alonso FC; Blackburn K; Copsey L; Drzewiecki J; Fundo A; Le Gall A; Gomez S; Javaid H; Lence CF; Martin NM; Mydlowski C; Smith GC
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3942-5. PubMed ID: 18579376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase.
    Kinoshita T; Nakanishi I; Warizaya M; Iwashita A; Kido Y; Hattori K; Fujii T
    FEBS Lett; 2004 Jan; 556(1-3):43-6. PubMed ID: 14706823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.
    Kim IK; Stegeman RA; Brosey CA; Ellenberger T
    J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors.
    Nilov DK; Yashina KI; Gushchina IV; Zakharenko AL; Sukhanova MV; Lavrik OI; Švedas VK
    Biochemistry (Mosc); 2018 Feb; 83(2):152-158. PubMed ID: 29618301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.